Loading
Life sciences · Journal article
Clinica Chimica Acta; International Journal of Clinical Chemistry · July 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background. The role of hyperuricemia in cardiometabolic multimorbidity (CMM) needs to be further confirmed. We aimed to investigate the impact of hyperuricemia on cardiometabolic multimorbidity, and to explore the metabolic mechanisms.Methods. We conducted a prospective cohort study using data from 422,058 participants in the UK Biobank. Cardiometabolic multimorbidity was defined as having two or more cardiometabolic diseases (CMDs) identified from linked primary care, hospital, and death registry records. Cox and multistate model was used to examine the role of hyperuricemia in the progression of CMM. Elastic net regression was employed to identify metabolites associated with hyperuricemia, and a weighted hyperuricemia metabolic score was calculated to assess its association with CMM.Results. During a median follow-up of 13.65 years, 55,092 developed CMDs, 6484 progressed to CMM, and 2234 died with CMM. Compared with participants without hyperuricemia, those with hyperuricemia had increased risks of any CMDs (HR = 1.23, 95% CI: 1.20-1.26, P < 0.001), and CMM (HR = 1.32, 95% CI: 1.23-1.42, P < 0.001). Mendelian randomization confirmed causal effects of hyperuricemia on CMDs and CMM. Furthermore, hyperuricemia metabolic score composed of 126 differential metabolites was significantly associated with CMDs (HR = 1.24, 95% CI: 1.21-1.27) and CMM (HR = 1.36, 95% CI: 1.28-1.44). In multi-state analyses, the metabolic score was associated with higher risks of transition from health to CMD (HR = 1.25, 95% CI: 1.22-1.28) and from CMD to CMM (HR = 1.15, 95% CI: 1.07-1.22).Conclusions. In this large cohort study, hyperuricemia was both observationally and genetically associated with increased risk of cardiometabolic diseases and subsequent progression to cardiometabolic multimorbidity. Hyperuricemia-related metabolic signatures may provide additional insights into the biological processes underlying cardiometabolic disease progression.